Broad Clinical Labs Sets New GUINNESS WORLD RECORDS™ Title for Fastest DNA Sequencing Technique
BOSTON, Oct. 16, 2025 /PRNewswire/ — Broad Clinical Labs (BCL), in collaboration with Roche Sequencing Solutions and Boston Children’s Hospital, today announced official recognition by Guinness World Records for achieving the fastest DNA sequencing technique to date.
Ellis Bio and UChicago Announce Breakthrough Ultra-Mild Bisulfite Sequencing Technology
NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present insights from its enLIGHTEN™ Discovery Platform, and additional data from the CAN-2409 (aglatimagene besadenovec) program in non-small cell lung cancer (NSCLC), through two accepted poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland.
PhenoVista Biosciences and Carolina Molecular Announce Partnership to Extend Multi-omic Data Access to Clients
SAN DIEGO, CA – September 11, 2025 – PhenoVista Biosciences and Carolina Molecular announce a partnership to combine their complementary CRO service capabilities to expand client access to broader multi-omic data.
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present insights from its enLIGHTEN™ Discovery Platform, and additional data from the CAN-2409 (aglatimagene besadenovec) program in non-small cell lung cancer (NSCLC), through two accepted poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland.
Promega and Watchmaker Genomics Announce Strategic Partnership to Advance Molecular Analysis with Next-Generation Reverse Transcriptase
Madison, WI and Boulder, CO – Promega Corporation has entered a strategic partnership with Watchmaker Genomics to license a novel engineered reverse transcriptase. Designed for enhanced accuracy and sensitivity in RNA analysis, the enzyme will enhance Promega capabilities to manufacture and deliver both catalog and customized solutions for clinical, applied and pharmaceutical molecular applications.
Twist Bioscience Collaborates with Synthetic Design Lab
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Sep. 2, 2025– Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL).
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel’s Research Advisory Board (RAB).
Mass General Brigham Launches Genetic Test Developed in Collaboration with Broad Clinical Labs to Predict Risk Across Eight Cardiovascular Conditions
BOSTON, Sept. 3, 2025 /PRNewswire/ — In a step forward for genomic-driven preventive medicine, Mass General Brigham Personalized Medicine and the Massachusetts General Hospital’s Cardiovascular Disease Prevention Center and Center for Genomic Medicine today announced the launch of an innovative genetic test designed to estimate an individual’s inherited risk for eight chronic cardiovascular conditions. The clinician-ordered test is now available to patients on a self-pay basis.
RNAConnect® Announces Commercial Launch of UltraMarathonRT® cDNA Synthesis and Amplification Kit for Enhanced Short-Read RNA Sequencing
RNAConnect, a leader in next-generation molecular biology tools, today announced the commercial launch of the UltraMarathonRT cDNA Synthesis
Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution
CAMBRIDGE, Mass., July 23, 2025 (Everygene) — Everygene launches no-cost genetic testing for cardiomyopathy patients, partnering with Broad Clinical Labs and Mass General Brigham to enhance diagnosis using advanced genomic technology.